Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Project cooperationUpdated on 9 April 2026

ASC1R

Filip Rázga

CEO at Selecta Biotech SE

Bratislava, Slovakia

About

ASC1R is an oligonucleotide-based therapeutic developed on the ESiNAR-X platform, targeting the SARS-CoV-2 RNA virus and intended for critically ill patients requiring intensive care to rapidly inhibit viral replication.

Status: Transitioning into Phase I clinical development, alongside GMP production of the drug substance and finished drug product.

We are seeking investments and partnerships to support the execution of clinical trials.

Similar opportunities